Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 13/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476322 | 1.00 | PPARG (0.50) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6476336 | 0.91 | PPARG (0.47) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6476342 | 0.91 | PPARG (0.47) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6477106 | 0.89 | PPARG (0.49) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6477102 | 0.89 | PPARG (0.49) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6477448 | 0.88 | PPARG (0.48) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6477453 | 0.88 | PPARG (0.48) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6531209 | 0.88 | PPARG (0.59) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6486611 | 0.85 | PPARG (0.65) | PPARGNPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL6486618 | 0.85 | PPARG (0.65) | PPARGNPC1RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919362-B2 | Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2005-07-19 | — | — | US | disclosed |
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | CYP2F1, CYP11B2, CYP4B1 | PPARG 414/4885NPC1 1716/4885RAB9A 3361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.